Tuesday , March 21 2023

Theradiag: January 15, 2019 – THERADIAG reaffirms its leading position in the monitoring of biotherapy with a new CE mark


THERADIAG reaffirms its leadership role in the monitoring of biotherapy CE marking of a new test

Cosentyx®, 12th CE mark of the TRACKER® series

Croissy-Beaubourg, January 15, 2019, at 18:00 CET THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in diagnostics in vitro and Theranostic announces today got the CE mark for the kit monitoring from Cosentyx® (Secukinumab)Day 12th LISA TRACKER® biotherapeutic control test for psoriasis, psoriatic arthritis and ankylosing spondylitis.

" With 12 CE mark tests for its LISA TRACKER® series, Theradiag is the only company in the world that offers most of the biotherapy used in the treatment of autoimmune and inflammatory diseases. Our commitment to maintaining this leading position is to develop a set of coinsring for all market biotherapies that are current and future in our therapeutic areas that are car diseases-immunes and cancer. The CE marking for Cosentyx® has been announced today reaffirms this dynamics Comments Pierre Morgon, President of Theradiag.

Cosentyx® / secukinumab is a monoclonal antibody blocks the activity of protein proteins. , immune system (interleukin) IL17A. WithAs a blocking effect of this substance, it reduces inflammatory processes that can affect psoriasis, psoriatic arthritis and ankylosing spondylitis.

Ankylosing spondylitis and psoriatic arthritis are chronic inflammatory diseases of the joints and spine that affect about five million people in Europe.

Only in the second quarter of 2018, Cosentyx generated revenues of more than $ 700 million.

About Theradiag

With its experience in distributing, developing and manufacturing in vitro diagnostic tests, Theradiag develops and develops therapeutic tests (treatment and diagnostic alliance) that determine effectiveness of biotherapyautoimmune diseases and cancer. Theradiag participates thus the development of "personalized medicine" by promoting individualisation of treatment, t their effectiveness and resistance prevention. Theradiag sells the LISA TRACKER® range CE, which is a complete multiparametric diagnostic solution for patients with biotherapy-treated autoimmune diseases. The company is located in Marne-la-Vallée and has over 65 employees.

For more information on Theradiag, visit our website: www.theradiag.com



Alize RP

Investor Relations

Financial communication and. T.

Press relations

Fabienne François, CFO

Investor Relations

Caroline Carmagnol

Tel. : 01 64 62 10 12

Valentine Brouchot

Tel. : 01 44 54 36 64

[email protected]

Tel. : 01 44 71 94 94

[email protected]

[email protected]

Source link